β2-Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma

Journal of Allergy and Clinical Immunology

Volumn 101, Issue 3, 1998, Pages 337-341

  Aziz, Imran ^a   Hall, Ian P ^a   McFarlane, Lesley C ^b   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Albuterol; Asthma; Desensitization; Formoterol; 2 adrenoceptor

Indexed keywords

FORMOTEROL; FORMOTEROL FUMARATE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; ETHANOLAMINE DERIVATIVE; GLYCINE; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; BETA ADRENERGIC RECEPTOR BLOCKING; BRONCHODILATATION; BRONCHUS REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DESENSITIZATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; DOSE RESPONSE; DRUG EFFECT; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; GENETICS; HEART RATE; INHALATIONAL DRUG ADMINISTRATION; LYMPHOCYTE; METABOLISM; MIDDLE AGED; PEAK EXPIRATORY FLOW; POLYMERASE CHAIN REACTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GLYCINE; HEART RATE; HUMANS; LYMPHOCYTES; MALE; MAXIMAL MIDEXPIRATORY FLOW RATE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA;

EID: 0031594494     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70245-3     Document Type: Article

References (11)

1. Grove, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995;346: 201-6.
2. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity alter chronic dosing with eformoterol in patients with asthma. Am J Med 1994;97:29-37.
3. Newnham DM, Grove A, McDevitt DG, Lipworth BJ. Subsensitivity of bronchodilator and systemic beta-2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995;50:497-504.
4. Lenfant C. Global initiative for asthma: global strategy for asthma management and prevention. National Institutes of Health; National Heart, Lungs, and Blood Institute; 1995. Publication no. 95-3659.
5. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
6. 2-adrenoceptor polymorphism is associated with susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet 1997; 350:995-9.
7. American Thoracic Society. Standardisation of spirometry-update. Am Rev Respir Dis 1987;136:1285-98.
8. 2-adrenoceptor function in normal and asthmatic subjects. Eur J Clin Pharmacol 1993;45: 535-8.
9. 2-adrenoceptor polymorphism with lower airways reactivity in asthmatic subjects. Lancet 1995;345:1213-4.
10. 2-adrenoceptor subsensitivity induced by formoterol. Br J Clin Pharmacol 1996;42:654-5.
11. Green SA, Turki J, Hall IP, Liggett SB. Implications of genetic variability of human 2-adrenergic receptor structure. Pulm Pharmacol 1995;8:1-10.